Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 3/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | RHOC | P08134 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | THRB | P10828 | 1/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL153886 | 1.00 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL909379 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL249095 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL137843 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL5072672 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL3832 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL7703363 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL7037659 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL6064039 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL7102147 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10062 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| US-12544341-B2 | Methods of preparing multiphase statin and omega-3 fatty acid soft capsule formulations | CATALENT ONTARIO LIMITED (CA) | 2026-02-10 | — | — | US | claimed |
| US-20250366785-A1 | METHODS FOR PROCESSING, ENRICHMENT, DELIVERY, FORMULATION, AND UPTAKE FOR SUPPLEMENTS AND PHARMACEUTICALS | VAN DE CASTEELE RUSSELL (US) | 2025-12-04 | — | — | US | claimed |
| US-12453746-B2 | Use of akkermansia muciniphila in preparation of pharmaceutical composition or health care product composition for improving metabolic syndrome | Guangzhou Zhiyi Biotechnology Co., Ltd. (CN) | 2025-10-28 | — | — | US | claimed |
| WO-2025202837-A1 | PALATABLE ICOSAPENT ETHYL FORMULATION WITH STATIN AND METHOD THEREOF | ALTHERA LABORATORIES INDIA PVT. LTD. (IN) | 2025-10-02 | — | — | WO | claimed |
| EP-4615409-A1 | AN ORALLY DISINTEGRATING TABLET CONTAINING ATORVASTATIN AND PROCESS OF PREPARING THE SAME | Novumgen Limited (GB) | 2025-09-17 | — | — | EP | claimed |
| EP-3984991-B1 | METHOD FOR SYNTHESIZING ATORVASTATIN CALCIUM INTERMEDIATE BY USING MULTI-COMPONENT ONE-POT METHOD | ZHEJIANG HONGYUAN PHARMA CO LTD (CN) | 2025-06-18 | — | — | EP | claimed |
| CN-120053386-A | Oral preparation containing bevacizidine and statin drugs and preparation process thereof | 甘李药业股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-20250170187-A1 | USE OF AKKERMANSIA MUCINIPHILA IN PREPARATION OF PHARMACEUTICAL COMPOSITION OR HEALTH CARE PRODUCT COMPOSITION FOR IMPROVING METABOLIC SYNDROME | Guangzhou Zhiyi Biotechnology Co., Ltd. (CN) | 2025-05-29 | — | — | US | claimed |
| CN-119970666-A | Compound amlodipine atorvastatin calcium tablet and production compounding device | 浙江长典药物技术开发有限公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2001074348-A2 | VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION | BRISTOL-MYERS SQUIBB CO. (US) | 2001-10-11 | — | — | WO | claimed |
| WO-2001036384-A1 | POLYMORPHIC FORM OF ATORVASTATIN CALCIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-05-25 | — | — | WO | claimed |
| WO-2001028999-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM | EGIS Gyógyszergyár Rt. (HU) | 2001-04-26 | — | — | WO | claimed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | claimed |
| WO-2000071116-A1 | PROCESS FOR THE PRODUCTION OF AMORPHOUS ATORVASTATIN CALCIUM | RANBAXY LABORATORIES LIMITED (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1045691-A1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | claimed |
| EP-1037623-A1 | ANTIHYPERLIPIDEMIC STATIN-LP(A) INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | claimed |
| WO-1999030704-A1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1999030706-A1 | ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |